Wong IY, et al. - Researchers assessed the effectiveness of half-dose verteporfin photodynamic therapy (hd-PDT) and standard-dose photodynamic therapy (sd-PDT) when combined with ranibizumab in the treatment of polypoidal choroidal vasculopathy. All enrollees received an injection of ranibizumab and PDT treatment at baseline. The overall mean age of the subjects included in this study was 69.3 ± 9.4 years. In general, the capability of hd-PDT to produce similar results as sd-PDT was seen. When baseline vision was 20/50 or better, or when there were 3 or less polyps on indocyanine green angiography, hd-PDT revealed superior results on subgroup analysis.